| Document |
Document Title |
|
WO/2005/023261A1 |
The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be su...
|
|
WO/2005/023785A1 |
A process for producing 2'-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde which comprises reacting 2'-cyanobiphenyl-4-carbaldehyde with an azide salt; and a process for producing high-purity crystals of 2'-(1H-tetrazol-5-yl)biphenyl-4-carba...
|
|
WO/2005/020899A2 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/021535A2 |
A method of removing the triphenylmethane protecting group from 1-triphenylmethyl-5-(4'-subst. methyl-1,1‘-biphenyl-2-yl)-1H-tetrazoles of general formula I wherein R represents the groups of formulae and where R1, R2 and R3 can be H, ...
|
|
WO/2005/020921A2 |
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Even more specifical...
|
|
WO2004012733A9 |
This invention relates to the use of certain compounds for the treatment of diseases that are responsive to antiangiogenetic therapy. Excessive angiogenesis occurs in diseases such as cancer, diabetic blindness, age-related macular degen...
|
|
WO/2005/021508A1 |
This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the like: ...
|
|
WO/2005/019167A2 |
Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula (I) wherein A, W, X, Z, R1-R3, and R8 are as defined in the specification, are provided. Also provided are methods of treating or preventing...
|
|
WO/2005/019204A1 |
A process for the preparation of compounds of formula (III), intermediates useful for the synthesis of cilostazol, which process comprises reacting haloimine of formula (V) wherein X is halogen, with trimethylsilyl azide.
|
|
WO/2005/019147A2 |
There are described compounds of formula (I) wherein X1 and X2 are each independently of the other fluorine, chlorine or bromine; A1 and A2 are, for example, a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge; R1 and R2 are, ...
|
|
WO/2005/019211A2 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at le...
|
|
WO/2005/014602A1 |
The present invention relates to a method for preparing substituted tetrazoles, compounds obtained according to this method, new reactants and new tetrazole derivatives.
|
|
WO/2005/014560A1 |
A process for the preparation of phenyltetrazole derivatives of formula (II) wherein R and Y are as defined in the disclosure, by direct ortho-metallation of (tetrazol-5-&gammad l)benzene. The compounds of formula (II) are useful interme...
|
|
WO/2005/014525A2 |
The invention is directed to a bi-aryl compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or disease...
|
|
WO/2005/014563A1 |
The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerativ...
|
|
WO/2005/011646A2 |
Nitrooxy derivatives of the angiotensin-II receptor blockers Iosartan vaalsartan, candesartan, telmisartan, eprosartan and olmesartan and related compounds of formula (I): R-(Y-ONO2)s wherein R is of formula (II) or (III): R0 is e.g: and...
|
|
WO/2005/012267A1 |
A process for producing an alkoxytetrazol-1-ylbenzaldehyde compound represented by the general formula (2): (wherein A1 represents alkoxy and A2 represents hydrogen, alkyl, or fluoroalkyl), characterized by reacting a 1-(alkoxyphenyl)-1H...
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/007099A2 |
The invention is directed to biaryl compounds with two six membered rings fused wherein at least one six membered ring is substituted with a thiophenyl or furanyl ring. Useful in the inhibition of PKB kinase, the treatment of cancer, or ...
|
|
WO/2005/003105A1 |
A directly synthetic method for preparing tris-alkylated 1,4,7,10-tetraazacyclododecanes by the reactions of 1,4,7,10-tetraazacyclododecane (cyclen) and appropriate electrophiles is accomplished in high yield. The method provides operati...
|
|
WO/2005/000800A1 |
This invention relates to a class of compounds having the general formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases ...
|
|
WO/2005/000823A1 |
The invention relates to a method of preparing cyclene having formula (I) from triethylenetetraamine having formula (VIII) or ethylenediamine having formula (VIII'). The inventive method is characterised in that it comprises one of the f...
|
|
WO/2004/113277A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+ related disease.
|
|
WO/2004/113275A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
|
|
WO/2004/111018A1 |
Valsartan of formula (I) is prepared by hydrolysis of valsartan benzyl ester with an alkali metal hydroxide, washing with an organic solvent, acidifying with hydrochloric acid and isolating valsartan from the reaction mixture.
|
|
WO/2004/111017A1 |
The present invention relates to novel diphenylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, and to pharmaceutical compositions compris...
|
|
WO/2004/106280A1 |
A compound having a calcium-sensitive receptor antagonism; and a pharmaceutical composition comprising the compound. In particular, a calcium receptor antagonist; and a curative for osteoporosis. More specifically, a compound of the form...
|
|
WO/2004/101534A1 |
From the starting 4-bromomethyl-2'-(1-triphenylmethyltetrazol-5-yl)biphenyl, N-[(2'(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl)methy
l]-(L)-valine benzyl ester of formula 7 is obtained via a reaction with L-valine benzyl ester, and ...
|
|
WO/2004/101535A1 |
The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administerin...
|
|
WO/2004/098591A2 |
The present invention relates to compounds that act as inhibitors of QC including those represented by the general formulae ( 1 to 9): and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down...
|
|
WO/2004/099134A2 |
The present invention relates dipeptidyl peptidase IV inhibition and, more particularly, relates to glutaminyl derivatives, wherein the glutamin residue is bound in a peptide manner to a moiety which imitates the amino acid residue proli...
|
|
WO/2004/094391A2 |
Provided are process for the preparation of valsartan and the precursors thereof and processes for preparing Valsartan containing less than about 5000 ppm residual solvent.
|
|
WO/2004/094392A1 |
Provided is a process for preparing valsartan substantially free of its isoleucine analogue and precursor thereof. The process for preparing valsartan comprising the step of: a) obtaining one or more samples of at least a single valine o...
|
|
WO/2004/091724A1 |
The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositio...
|
|
WO/2004/089925A1 |
The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.
|
|
WO/2004/089360A1 |
This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of o...
|
|
WO/2004/087681A1 |
The present invention relates to a novel amorphous form of valsartan, to a process for its preparation and to a pharmaceutical composition containing it.
|
|
WO/2004/084898A1 |
The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemo...
|
|
WO/2004/083192A1 |
Provided are crystalline and amorphous form of valsartan, and processes for their preparation.
|
|
WO/2004/080480A1 |
Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.
|
|
WO/2004/080947A1 |
A compound represented by the following general formula (I), its salt, its solvate or its N-oxide or prodrugs thereof: (I) wherein R1 and R2 represent each an optionally substituted cyclic group, etc.; W is a spacer having from 1 to 6 ca...
|
|
WO/2004/080377A2 |
This invention relates to compounds of the general formula (I) useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.
|
|
WO/2004/080984A1 |
Novel insecticidal phthalamide derivatives of the formula (I), in which is a 5- or 6- membered heterocyclic group, a plurality of processes for preparing these compounds and their use for controlling pests.
|
|
WO/2004/078734A1 |
This invention relates to novel tetrazole and oxadiazalone β-amino acids derivatives of the formula (I, II), wherein G is (III, IV) wherein R1 through R4 are defined as in the specification, pharmaceutical compositions containing them a...
|
|
WO/2004/076425A1 |
An improved method of synthesizing a macrocyclic tetraamido compound includes protecting the amino portion of an amino carboxylic acid to form a protected amino carboxylic acid; exposing the protected amino carboxylic acid to a first sol...
|
|
WO/2004/073705A1 |
Novel 1-phenyl-2-monoalkylcarboxylic derivatives, the process for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer’s disease.
|
|
WO/2004/074267A1 |
The invention relates to the metal complexes of general formula (I), wherein Hal represents bromine or iodine, and A1 and A2 have different meanings. The inventive metal complexes are suitable for use as contrast media.
|
|
WO/2004/071426A2 |
The present invention is related to compounds, their intermediates, processes for their preparation and use, and pharmaceutical compositions comprising the compounds. The novel compounds are useful in therapy, and in particular for the t...
|
|
WO/2004/069196A2 |
Novel NH-substituted fused triazoles are inhibitors of the bacterial enzyme S aureus methionyl t RNA synthetase and are of use in treating bacterial infections.
|
|
WO/2004/069158A2 |
The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of...
|
